Возможности альгинатов в терапии гастроэзофагеальной рефлюксной болезни
Возможности альгинатов в терапии гастроэзофагеальной рефлюксной болезни
Бордин Д.С., Машарова А.А. Возможности альгинатов в терапии гастроэзофагеальной рефлюксной болезни. Consilium Medicum. 2008; 10 (8): 5–9.
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Список литературы
1. Dent J, El-Serag HB, Wallander MA et al. Epidemiology of gastro-oesophageal reflux disease: A systematic review. Gut 2005; 54: 710–7.
2. Лазебник Л.Б., Бордин Д.С., Машарова А.А. Современное понимание гастроэзофагеальной рефлюксной болезни: от Генваля к Монреалю. Экспер. и клин. гастроэнтер. 2007; 5: 4–10.
3. Васильев Ю.В. Гастроэзофагеальная рефлюксная болезнь. Лазебник Л.Б. (ред.) Избранные главы клинической гастроэнтерологии. М.: Анахарсис, 2005; 7–30.
4. Vakil N, van Zanden SV, Kahrilas P et al. The Monreal Definition and Classification of Gastroesophageal Reflux Disease: A Global Evidence-Based Consensus. Am J Gastroenterol 2006; 101: 1900–20.
5. Лазебник Л.Б. Изжога и гастроэзофагеальная рефлюксная болезнь: проблемы и решения. Тер. арх. 2008; 2: 5–11.
6. Dickman R, Fass R. The pathophysiology of GERD. F.A.Grranderath, T.Kamolz, R.Pointher (eds.) Gastroesophageal Reflux Disease. Principles of Disease, Diagnosis, and Treatment. New York: Springer Wien, 2006; 13–22.
7. Fass R, Naliboff B, Higa L et al. Differential effect of long-term esophageal acid exposure on mechanosensitivity and chemosensitivity in humans. Gastroenterology 1988; 115: 1363–73.
8. Tobey NA, Carson JL, Alkiek RA, Orlando RC. Dilated intercellular spaces: a morphological feature of acid reflux – damaged human esophageal epithelium. Gastroenterology 1996; 111: 1200–5.
9. Orlando RC. Pathophysiology of gastroesophageal reflux disease. D.O.Castell, J.E.Richter (eds.). Esophagus, 3d ed. Philadelphia: Lippincot Williams & Wilkins; 409–19.
10. Van Pinxteren B, Numan ME, Bonis PA et al. Shortterm treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2004; 4: CD002095.
11. Martinez SD, Malagon I, Garewal HS, Fass R. Abstract: non-erosive reflux disease (NERD) – is it really just a mild form of gastroesophageal reflux disease (GERD)? Gastroenterology 2001; A-424: 2163.
12. Pehlivanov ND, Liu J, Mittal R. Abstract: sustained esophageal contraction: a motor correlate of heartburn symptom. Gastroenterology 1999; 118: A1062, G4613
13. Fass R. Focused clinical review: noneroseve reflux disease. Medscape Gastroenterol 2001; 3: 1–13.
14. Sarkar S, Aziz Q, Woolf CJ at al. Contribution of central sensitisation to the development of non-cardiac chest pain. Lancet 2000; 356: 1154–9.
15. Trimble KC, Pryde A, Heading RC. Lowered oesophageal sensory thresholds in patients with symptomatic but not excess gastro-oesophageal reflux: evidence for a spectrum of visceral sensitivity in GORD. Gut 1995; 37: 7–12.
16. Мананников И.В. Эпидемиология гастроэзофагеальной рефлюксной болезни в Москве. Автореф. дис… канд. мед. наук. М., 2005.
17. McDonald-Haile J, Bradley LA, Bailey MA et al. Relaxation training reduces symptom reports and acid exposure in patients with gastroesophageal reflux disease. Gastroenterology 1994; 107: 61–9.
18. Fass R, Malagon I, Naliboff B et al. Abstract: effect of psychologically induced stress on symptom perception & autonomic nervous system response of patients with erosive esophagitis and non erosive reflux disease. Gastroenterology 2000; 118: A637, 3250.
19. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005; 100: 190–200.
20. Vigeri S, Tonini M, Scarpinato C, Savarino V. Improving opportunities for effective management of gastro-esophageal reflux disease. Dig Liv Dis 2001; 33: 719–29.
21. Holtmann G. The clinical usefulness of PPIs: Are they all the some? (Yes) In: "PPIs: Are they all the some? – The Ultimate Debate". – 10 UEGW, Absrtact Book. Geneva, 2002; 10–1.
22. Bell NJV, Burget D, Howden CW et al. Appropriate acid suppression for the management of gastro-esophageal reflux disease. Digestion 1992; 51 (Suppl. 1): 59–67.
23. Стандарты. Диагностика и терапия кислотозависимых заболеваний, в том числе ассоциированных с Helicobacter pylori (Третье Московское соглашение). Экспер. и клин. гастроэнтер. 2005; 3: 3–6.
24. Tytgat GN, McColl K, Tack J et al. New algorithm for the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2008; 27: 249–56.
25. Mandel KG, Daggy BP, Brodie DA, Jacoby HI. Review article: alginate-raft formulations in the treatment of heartburn and acid reflux. Aliment Pharmacol Ther 2000; 14: 669–90.
2. Лазебник Л.Б., Бордин Д.С., Машарова А.А. Современное понимание гастроэзофагеальной рефлюксной болезни: от Генваля к Монреалю. Экспер. и клин. гастроэнтер. 2007; 5: 4–10.
3. Васильев Ю.В. Гастроэзофагеальная рефлюксная болезнь. Лазебник Л.Б. (ред.) Избранные главы клинической гастроэнтерологии. М.: Анахарсис, 2005; 7–30.
4. Vakil N, van Zanden SV, Kahrilas P et al. The Monreal Definition and Classification of Gastroesophageal Reflux Disease: A Global Evidence-Based Consensus. Am J Gastroenterol 2006; 101: 1900–20.
5. Лазебник Л.Б. Изжога и гастроэзофагеальная рефлюксная болезнь: проблемы и решения. Тер. арх. 2008; 2: 5–11.
6. Dickman R, Fass R. The pathophysiology of GERD. F.A.Grranderath, T.Kamolz, R.Pointher (eds.) Gastroesophageal Reflux Disease. Principles of Disease, Diagnosis, and Treatment. New York: Springer Wien, 2006; 13–22.
7. Fass R, Naliboff B, Higa L et al. Differential effect of long-term esophageal acid exposure on mechanosensitivity and chemosensitivity in humans. Gastroenterology 1988; 115: 1363–73.
8. Tobey NA, Carson JL, Alkiek RA, Orlando RC. Dilated intercellular spaces: a morphological feature of acid reflux – damaged human esophageal epithelium. Gastroenterology 1996; 111: 1200–5.
9. Orlando RC. Pathophysiology of gastroesophageal reflux disease. D.O.Castell, J.E.Richter (eds.). Esophagus, 3d ed. Philadelphia: Lippincot Williams & Wilkins; 409–19.
10. Van Pinxteren B, Numan ME, Bonis PA et al. Shortterm treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2004; 4: CD002095.
11. Martinez SD, Malagon I, Garewal HS, Fass R. Abstract: non-erosive reflux disease (NERD) – is it really just a mild form of gastroesophageal reflux disease (GERD)? Gastroenterology 2001; A-424: 2163.
12. Pehlivanov ND, Liu J, Mittal R. Abstract: sustained esophageal contraction: a motor correlate of heartburn symptom. Gastroenterology 1999; 118: A1062, G4613
13. Fass R. Focused clinical review: noneroseve reflux disease. Medscape Gastroenterol 2001; 3: 1–13.
14. Sarkar S, Aziz Q, Woolf CJ at al. Contribution of central sensitisation to the development of non-cardiac chest pain. Lancet 2000; 356: 1154–9.
15. Trimble KC, Pryde A, Heading RC. Lowered oesophageal sensory thresholds in patients with symptomatic but not excess gastro-oesophageal reflux: evidence for a spectrum of visceral sensitivity in GORD. Gut 1995; 37: 7–12.
16. Мананников И.В. Эпидемиология гастроэзофагеальной рефлюксной болезни в Москве. Автореф. дис… канд. мед. наук. М., 2005.
17. McDonald-Haile J, Bradley LA, Bailey MA et al. Relaxation training reduces symptom reports and acid exposure in patients with gastroesophageal reflux disease. Gastroenterology 1994; 107: 61–9.
18. Fass R, Malagon I, Naliboff B et al. Abstract: effect of psychologically induced stress on symptom perception & autonomic nervous system response of patients with erosive esophagitis and non erosive reflux disease. Gastroenterology 2000; 118: A637, 3250.
19. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005; 100: 190–200.
20. Vigeri S, Tonini M, Scarpinato C, Savarino V. Improving opportunities for effective management of gastro-esophageal reflux disease. Dig Liv Dis 2001; 33: 719–29.
21. Holtmann G. The clinical usefulness of PPIs: Are they all the some? (Yes) In: "PPIs: Are they all the some? – The Ultimate Debate". – 10 UEGW, Absrtact Book. Geneva, 2002; 10–1.
22. Bell NJV, Burget D, Howden CW et al. Appropriate acid suppression for the management of gastro-esophageal reflux disease. Digestion 1992; 51 (Suppl. 1): 59–67.
23. Стандарты. Диагностика и терапия кислотозависимых заболеваний, в том числе ассоциированных с Helicobacter pylori (Третье Московское соглашение). Экспер. и клин. гастроэнтер. 2005; 3: 3–6.
24. Tytgat GN, McColl K, Tack J et al. New algorithm for the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2008; 27: 249–56.
25. Mandel KG, Daggy BP, Brodie DA, Jacoby HI. Review article: alginate-raft formulations in the treatment of heartburn and acid reflux. Aliment Pharmacol Ther 2000; 14: 669–90.
Авторы
Д.С.Бордин, А.А.Машарова
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.